Cellular and T cell engager Immunotherapy
A German multicenter real-world analysis of talquetamab in 102 patients with relapsed/refractory multiple myeloma
Jan H. Frenking, MD (he/him/his)
Medical Doctor
Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
Heidelberg, Baden-Wurttemberg, Germany